Vir Biotechnology Inc
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Current Price
$8.79
-3.30%Vir Biotechnology Inc (VIR) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Vir Biotechnology Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $65.50M. Gross profit (TTM) is $65.47M. EBITDA is $-425.52M. Earnings per share (EPS) is $-3.16. The P/E ratio is -2.77. Market capitalization is $1.23B.
Free cash flow (FCF) is $-396.36M. EPS growth CAGR is -2.41%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Vir Biotechnology Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
